For the first quarter of the fiscal year ending December 2026, revenue was 11,256 million yen (up 4,612 million yen Year-over-Year), and operating income turned to a profit of 3,244 million yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4565","jir_company_name":"Nexsera Pharma, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-05-01","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4565-20260501-01.pdf","jir_short_summary":"For the first quarter of the fiscal year ending December 2026, revenue was 11,256 million yen (up 4,612 million yen Year-over-Year), and operating income turned to a profit of 3,244 million yen.","jir_summary":"### Overview of Financial Results\nIn the first quarter of the fiscal year ending December 2026, revenue increased by 4,612 million yen Year-over-Year to 11,256 million yen, primarily due to the achievement of multiple milestones. Research and development expenses decreased by 780 million yen to 3,028 million yen, and selling, general and administrative expenses also decreased by 131 million yen to 3,570 million yen. As a result, operating income turned positive to a profit of 3,244 million yen, with income before income taxes and net income for the quarter also returning to profit. Core operating income reached a profit of 5,495 million yen, reflecting strengthening of the financial base.\n\n### Progress in Business Activities and Partnerships\nSignificant commercial and development progress was made, including signing a license agreement for the Duchenne muscular dystrophy treatment vamorolone in Japan and the APAC region, filing for manufacturing and marketing approval of dalorexant in South Korea, and entering a license agreement for GPCR-targeting programs with a European venture company. The acquisition of partner Centessa Pharmaceuticals Limited by Eli Lilly was also announced, with the company holding rights to receive milestone and royalty income. Furthermore, multiple partnerships achieved milestones and commenced clinical trials, contributing to future growth prospects.","jir_financial_highlights":"Revenue: 11,256 million yen (Up 4,612 million yen Year-over-Year)\nResearch and Development Expenses: 3,028 million yen (Down 780 million yen Year-over-Year)\nSelling, General and Administrative Expenses: 3,570 million yen (Down 131 million yen Year-over-Year)\nOperating Income: Profit of 3,244 million yen (Turned to profit from a loss of 2,193 million yen Year-over-Year)\nIncome Before Income Taxes for the Quarter: Profit of 3,043 million yen (Turned to profit from a loss of 2,156 million yen Year-over-Year)\nNet Income for the Quarter: Profit of 1,793 million yen (Turned to profit from a loss of 760 million yen Year-over-Year)\nCore Operating Income: Profit of 5,495 million yen (Turned to profit from a loss of 625 million yen Year-over-Year)\nCash and Cash Equivalents: 11,597 million yen (Decreased by 8,767 million yen from the end of the previous consolidated fiscal year)","jir_category":"","jir_hashtags":"#NexseraPharma, #Earnings, #Biopharmaceuticals","jir_key_figures":"Revenue: 11,256 million yen (Up 4,612 million yen Year-over-Year)\nOperating Income: Profit of 3,244 million yen (Loss of 2,193 million yen in the previous Year-Over-Year quarter)\nCore Operating Income: Profit of 5,495 million yen (Loss of 625 million yen in the previous Year-Over-Year quarter)","jir_meta_title":"\u3010Nexsera Pharma\u3011Q1 2026 Earnings\uff5cRevenue 11.26 Billion Yen (Year-over-Year Growth)","jir_meta_description":"Nexsera Pharma, Inc. announces its consolidated financial results for the first quarter of the fiscal year ending December 2026. Revenue increased Year-over-Year and operating income turned positive. Key partnership agreements and milestone achievements are also reported.","jir_og_title":"\u3010Nexsera Pharma\u3011Q1 2026 Earnings\uff5cRevenue 11.26 Billion Yen (Year-over-Year Growth)","jir_og_description":"Achieved revenue growth and operating profitability in Q1 2026. Strengthened growth foundation through key partnerships and milestone achievements.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Year-over-Year Revenue Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q1 2025\\\",\\\"Q1 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[6634,11256],\\\"backgroundColor\\\":\\\"#4e79a7\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Year-over-Year Operating Income Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q1 2025\\\",\\\"Q1 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[-2193,3244],\\\"backgroundColor\\\":\\\"#f28e2b\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":false}}}}\"}, {\"jir_chart_id\": \"quarterly_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Year-over-Year Quarterly Profit Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q1 2025\\\",\\\"Q1 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Quarterly Profit\\\",\\\"data\\\":[-760,1793],\\\"backgroundColor\\\":\\\"#59a14f\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":false}}}}\"}, {\"jir_chart_id\": \"research_development_expense_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Year-over-Year R&D Expense Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q1 2025\\\",\\\"Q1 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"R&D Expenses\\\",\\\"data\\\":[3808,3028],\\\"backgroundColor\\\":\\\"#e15759\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"sg_and_a_expense_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Year-over-Year SG&A Expense Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q1 2025\\\",\\\"Q1 2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"SG&A Expenses\\\",\\\"data\\\":[3701,3570],\\\"backgroundColor\\\":\\\"#76b7b2\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":16880,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-44765","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n